Bio X Cell, a producer of monoclonal antibodies for pre-clinical research, has appointed Christopher Conway as its new CEO.
Christopher has significant experience in drug discovery in the small molecule and biologics realm, and was most recently the President of R&D at Curia.
He has also cycled through a series of commercial leadership roles at Johnson & Johnson, including Senior Vice President and Drug Discovery and Development business unit Head.
He also worked as the President of the R&D business unit, leading 20 sites globally.
“As my successor, Chris not only brings strong business and industry credentials, but an understanding and respect for Bio X Cell’s culture and mission to advance scientific discovery and innovation by providing the highest quality products and exceptional customer service,” said the Company’s founder, Klaus Lubbe.
Dr Lubbe sold a majority stake in BXC to Windjammer Capital Investors in November 2023 and remains involved, particularly with respect to new product development, as a board member and minority shareholder.
“During his tenure at AMRI/Curia, Chris held diverse leadership roles and helped the business continue to grow as the company evolved from founder-led to private equity ownership,” said Craig Majernik, Managing Director at Windjammer. “That experience, combined with his proven leadership skillset, commercial expertise and reach across the drug development industry, make him uniquely qualified to lead BXC through the next phase of growth and business expansion.”
